NewAmsterdam Pharma reports incentive grants pursuant to Nasdaq Listing Rule 5635(c)(4)

NAARDEN, Netherlands and MIAMI, Sept. 6, 2024 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company NV (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), an advanced clinical-stage biopharmaceutical company developing oral, non-statin-based medicines for patients at risk for cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”) for whom existing therapies are not sufficiently effective or well tolerated, today announced that the Compensation Committee of NewAmsterdam's Board of Directors has approved the grant of incentive stock options totaling 111,000 shares of NewAmsterdam common stock to three newly hired non-executive officers. The stock options were granted to the employees as an incentive to accept employment with NewAmsterdam under NewAmsterdam Pharma Company NV’s 2024 Incentive Plan (the “2024 Incentive Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $15.91 per share, which is equal to the closing price of the Company's common stock on September 3, 2024, the grant date, on the Nasdaq Stock Market. The shares to which the options relate will vest over a period of four years, with 25% of the shares vesting on the one-year anniversary of the respective vesting commencement dates and the remainder of the shares vesting thereafter in a series of 36 equal monthly installments, subject to each employee's continued employment with NewAmsterdam on such vesting dates. The options are subject to the terms of the 2024 Incentive Plan and the terms of an option award agreement covering the grant.

About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies are inadequate or poorly tolerated. We aim to address a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple Phase 3 trials, NewAmsterdam is evaluating obicetrapib, an oral, low-dose, once-daily CETP inhibitor, alone or in combination with fixed-dose ezetimibe as an LDL-C-lowering therapy to be used as an adjunct to statin therapy in patients at cardiovascular risk with elevated LDL-C where existing therapies are inadequate or poorly tolerated.

Company contact
Matthew Philippe
Phone: 1-917-882-7512
[email protected]